FPA144: Additional Phase I data

Data from 9 patients with FGFR2b-positive gastric cancer in the dose-escalation Part 1 of an open-label, international Phase

Read the full 186 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE